Autolus Therapeutics (NASDAQ:AUTL) Trading Up 4% – Still a Buy?

Autolus Therapeutics plc (NASDAQ:AUTL) was up 4% during mid-day trading on Friday . The company traded as high as $3.18 and last traded at $3.13. Approximately 2,001,397 shares were traded during mid-day trading, an increase of 39% from the average daily volume of 1,438,985 shares. The stock had previously closed at $3.01.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.45.

Autolus Therapeutics Trading Up 3.0 %

The firm’s 50-day moving average is $3.92 and its 200-day moving average is $3.99. The firm has a market cap of $824.88 million, a price-to-earnings ratio of -2.49 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm earned ($0.26) EPS. Analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth $43,000. Capstone Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter worth $51,000. Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares during the period. Herbst Group LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter worth $91,000. Finally, Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth $100,000. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.